Request Information

Microbial Analysis
At Warp Speed

Detecting multiple pathogens simultaneously
without enzymes, amplification or reagents

INVESTMENT IN DISCOVERY

Featured On

Price per Share of Common

$4.50

Minimum
Investment

111 Shares / $499.50

Number of Share Holders

Total Capital Raised*

Reg A Invest Now

Out Of This World
Technology

How is Check4™ different from other pathogen tests?

The Pandemic has taught the public much about medical testing, its limitations and effectiveness. Check4™ by IdentifySensors®, is not a PCR test, an antibody test or an antigen test. These are all outdated technologies developed 50 years ago, yet they still make up the vast majority of testing for infectious diseases today.

Check4™ is new patented technology that moves medical testing from a chemical reaction to a digital readout. It uses electronic pulses to measure precise levels of micro-electric currents that pass through viruses and bacteria. Each pathogen carries a digital signature, which is quickly identified in saliva and decoded through a small portable reader. When used, the reader transmits results wirelessly to the user’s smartphone in minutes.

In July 2022, this proprietary and patented technology moved from development stages while we were at Purdue University to the manufacturing stage with Jabil Healthcare. Soon after FDA approval, new devices will be manufactured by the millions for governments, health care systems, corporations and eventually we intend for personal use.

A Tricorder for pathogen detection

Check4™ by IdentifySensors Biologics® is a next-generation digital diagnostic platform intended to detect multiple pathogens within 5 minutes at the gene level. The platform eliminates the need for enzymatic amplification and reagents. Graphene sensor technology has moved diagnostics beyond chemical testing into a rapid digital platform as accurate as a PCR test but significantly more sensitive and cost effective. 

Printed graphene sensors isolate targeted viruses and bacteria from saliva and other bodily fluids within a handheld, Bluetooth device. The platform is intended to detect the genetic material of dozens of pathogens for over-the-counter and point-of-care use.

With a target price at a fraction of current molecular tests, Check4™ is intended to disrupt the PCR market for many infections. Future plans for the platform include rapidly detecting biomarkers and T-cell immunity, in conjunction with direct diagnosis to help clinicians predict infection severity and vaccine effectiveness among individual patients.

How It Works

1

Step One

Patients and other end-users deposit a small saliva sample into the Check4® device, which is about the size of a cell phone. If targeted DNA or RNA is present in saliva, digital signals passing through the graphene sensors trigger a molecular reaction and a cloud-based algorithm determines the results. If the targeted pathogen is absent in the saliva, a molecular reaction cannot occur, and the test is deemed negative. Future plans include the ability to test through other bodily fluids. 

2

Step Two

The reactions among the genetic material are unmistakable. The algorithm verifies the data and sends results to a user’s cell phone or to a clinical database in minutes. These sensors use no chemical additives and can be easily functionalized by the manufacturer for COVID, Flu, RSV and a host of other infections, including HIV, Lyme and hepatitis.

Check4™ Features

Fast & Accurate Saliva Self-Test

Our Team Worked in Partnership with Purdue University

All New Nanosensor Technology

Results Available In Minutes

iOS & Android Compatible

Protected by 5 Patents

Find out more about our Patents & Technologies

Facts at a Glance

Graphene sensors rapidly detect infections digitally from saliva

Breakthrough technology that is not PCR or antigen

No enzymes, amplification, reagents or lab work

Ultra-high accuracy and sensitivity from saliva and other bodily fluids

Targeted at half the price of PCR tests

Multiplex tests for multiple infections simultaneously

Test in less than five minutes

Results sent to smartphones, remote dashboard or a clinical database

Plans to functionalize for direct diagnosis, biomarkers and T-cell immunity

Data capturing for infectious diseases

INVESTMENT OVERVIEW

The Check4™ platform by IdentifySensors® represents a technological breakthrough, which electronically pinpoints genetic material of targeted pathogens in saliva. This portable self-test produces a digital signal that is analyzed in the cloud in less than three minutes with accuracy and sensitivity greater than PCR tests.

Solid-state electrodes enable almost instantaneous results without lab work, chemical reagents or amplification. In July 2022, the company partnered with Jabil Healthcare to optimize the technology for mass manufacturing. IdentifySensors® intends to significantly disrupt the diagnostics industry for multiple pathogens and realize substantial profits by 2023.

pathogen detection sensor reader in hand

$4.50

Price per Share of Common

111 Shares / $499.50

Minimum
Investment

421

Number of Share Holders

$9,098,112.55

Total Capital Raised*

Investors

Call our investment team:
(737) 757-8067
Reg A Invest Now

Offering Circular

CHECK4™ FAQS

What does IdentifySensors® Biologics do?

Check4™ is intended to be a fast, accurate and affordable saliva self-test for COVID-19 and a host of other infections. Results are displayed within minutes on a smartphone app, with accuracy that far exceeds current rapid home tests.

How is Check4™ different from all other COVID tests?

New CDC research shows that current rapid home tests give false results more than 50 percent of the time. Check4™ is intended to an over-the-counter rapid test with the accuracy of a PCR test. Reducing false negatives rapidly by this margin will be critical to slowing the spread and allowing people to return to normal.

Do healthcare professionals need to administer the test?

No. Check4™ is intended to be a simple self-test, similar to a home DNA test. Check4-COVID™ allows consumers to test their saliva on a device that connects to a smartphone. Results appear on the app within minutes in the privacy of a user’s home.

How does the test work?

Consumers buy a small, simple device and download the free smartphone app. A saliva sample is placed in the device, and the results appear within minutes on the app. It is intended that inexpensive replaceable cartridges will allow endless, affordable testing on each device.

How accurate is Check4™?

Following FDA approval, Check4™ intends to meet the gold-standard in hospital-grade molecular COVID testing with minimal false positives. This is significantly better than current home rapid tests.

Why does the test use a smartphone app?

Chemical-based tests often rely on visual indicators. Check4™ uses an electronic circuit, which enables a signal to be sent to smartphones. The app then reports results to health authorities, which is required by law.

What if I don’t have a smartphone?
The smartphone app allows multiple users on a single device. This enables family members who do not have smartphones to use the device and app belonging to someone with a smartphone.
Do I have to buy multiple devices to test other family members?
No. A family can share the same device. The smartphone app is intended to allow multiple users so family members can share the same app and device, while interchanging different test cartridges.
Is the Smartphone app HIPAA compliant? What happens to my personal information?
By law, all test results must be reported to state and federal health authorities. All information collected by the IdentifySensors app is confidential and shared only with government agencies that require it. Some test results are de-identified, meaning that names are removed from the test results. All data is treated by the same high standards as secure hospital records. The app is securely encrypted and fully HIPAA compliant.
How much will the test cost?
It is intended that the reusable reader will cost $130. Each test cartridge will cost less than $25. The accuracy of the test and the low cost are intended to promote more frequent testing.
How can I be sure the test is accurate?
World-renowned scientists at Purdue University, who specialize in infectious diseases, have been developing and verifying the test’s accuracy for commercialization. The test is intended to be available to consumers following FDA approval, which is anticipated this year.
What is the problem with current rapid tests?
New CDC research shows that more than 50 percent of current rapid test results are incorrect. Most PCR tests currently in use are expensive and take far too long for the results. These chemical-based tests often require samples to be transported to a laboratory for results.
When will the test be available to consumers?
Industry-leading scientists at Purdue University who specialize in infectious diseases have been developing and verifying the test for commercialization. The test is intended to be available to consumers following FDA approval this year.
Where will the test be sold?

Check4™ is intended to be sold online and through retail stores, such as pharmacies and grocery stores. High-volume commercial versions of the test are intended to be available to healthcare facilities and businesses through wholesale channels.

Can the test be used to minimize quarantine times?

Yes. Check4™ is intended to be fast, inexpensive and accurate, which enables frequent self-testing at home and without wait. Individuals infected with COVID-19, who quarantine at home, can self-test as often as they like to minimize quarantine times and return to their lives as soon as possible.

Is the test technology patented?
Yes, IdentifySensors holds several patents on various facets of the technology. Other patents are pending.
When will the product be available on the market?

Product development is in its final stages now. It is intended that the test will be available in 2023, following FDA approval.

What other virus and bacteria can Check4™ detect?
The unique technology enables the test to be easily modified for other pathogens, including other coronaviruses, influenza, Zika, dengue, HIV/AIDS, hepatitis C, Lyme disease, mumps, measles, chickenpox, and methicillin-resistant staphylococcus Aureus (MRSA), as well as foodborne pathogens.

In Partnership with Purdue University

When IdentifySensors® developed the concept for digital disease testing, the company knew it needed a world-class academic institution to verify the discovery and help move the technology to commercialization.

In 2019, IdentifySensors® partnered with the world-renowned Department of Inflammation, Immunology and Infectious Diseases at Purdue University.

In the spring of 2021, IdentifySensors® moved the technology from the research lab to the commercialization stage, where the work at Purdue is being optimized for large-scale, roll-to-roll manufacturing.

In the summer of 2022, IdentifySensors® completed its proof of concept and partnered with Jabil Healthcare to optimize the manufacturing process.

 

pathogen detection sensor reader in hand
pathogen detection sensor reader in hand

Proprietary and Patented Technology

Years ago, IdentifySensors® began developing and patenting nanosensors that detect pathogens that grow in food during long-distance transport. When the pandemic struck, scientists turned their research to a rapid COVID test based on the same technology.

Soon into the development stage, researchers realized the technology could serve as an all-new disruptive platform that could forever change the medical testing industry. Check4™ currently has several utility patents, with others pending.

How Your Investment Will Be Put to Work

The next step is to refine the designs for efficient large-scale commercialization and manufacturing. Your investment will help manufacture millions of Check4™ readers and test cartridges and help bring them to market soon.

 

pathogen detection sensor reader in hand

Ready to invest?

Help get this test to market soon and support the fast, accurate, and affordable smartphone-connected COVID self-test.
Reg A Invest Now

Offering Circular